LAVA-051

N/A

Report date: 2026/03/26 20:00:17

Base Information

Drug NameLAVA-051
Drug Alias NameLAVA-051
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionAnti-CD1dAnti-TRDV2
TargetsCD1d antigensT cell receptor delta variable 2
Therapy Area/IndicationsMultiple MyelomaLeukemia, Myeloid, AcuteLeukemia, Lymphocytic, Chronic, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNetherlandsFrance +[4] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesVu University Medical CenterLava Therapeutics NV
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesLava Therapeutics NV
Active IndicationsN/A
Inactive IndicationsMultiple MyelomaLeukemia, Myeloid, AcuteLeukemia, Lymphocytic, Chronic, B-Cell

Other Information

ATC CodeN/A
Related LinksN/A